Cargando…
Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis
Background: An optimal sequential systemic therapy for advanced hepatocellular carcinoma (HCC) has not been discovered. We developed a decision model based on available clinical trials to identify an optimal risk/benefit strategy for sequences of novel systemic agents. Methods: A Markov model was bu...
Autores principales: | Cabibbo, Giuseppe, Celsa, Ciro, Enea, Marco, Battaglia, Salvatore, Rizzo, Giacomo Emanuele Maria, Grimaudo, Stefania, Matranga, Domenica, Attanasio, Massimo, Bruzzi, Paolo, Craxì, Antonio, Cammà, Calogero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464739/ https://www.ncbi.nlm.nih.gov/pubmed/32752060 http://dx.doi.org/10.3390/cancers12082132 |
Ejemplares similares
-
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020) -
Hepatitis B Virus-Associated Hepatocellular Carcinoma
por: Rizzo, Giacomo Emanuele Maria, et al.
Publicado: (2022) -
Prognostic scores for hepatocellular carcinoma: none is the winner
por: Cammà, Calogero, et al.
Publicado: (2009) -
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals
por: Vernuccio, Federica, et al.
Publicado: (2022) -
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease
por: Pennisi, Grazia, et al.
Publicado: (2022)